Italia markets closed

Oxurion NV (0G99.L)

LSE - LSE Prezzo differito. Valuta in EUR.
Aggiungi a watchlist
0,0168-0,0014 (-7,69%)
Alla chiusura: 04:29PM GMT
Schermo intero
Chiusura precedente0,0182
Aperto0,0174
Denaro0,0000 x 0
Lettera0,0000 x 0
Min-Max giorno0,0166 - 0,0178
Intervallo di 52 settimane0,0166 - 0,0178
Volume151.464
Media VolumeN/D
Capitalizzazione6.516
Beta (5 anni mensile)0,31
Rapporto PE (ttm)N/D
EPS (ttm)-0,7590
Prossima data utiliN/D
Rendimento e dividendo (forward)N/D (N/D)
Data ex dividendoN/D
Stima target 1AN/D
  • GlobeNewswire

    Information on the Total Number of Voting Rights (Denominator) following Conversion Notice from NEGMA

    Information on the Total Number of Voting Rights (Denominator) following Conversion Notice from NEGMA Negma Group Investment Ltd. has converted 200 convertible bonds in Oxurion resulting in a EUR 500,000 capital increase. This is part of Negma Group Investment Ltd.’s EUR 15 million Capital Commitment1 that will allow Oxurion to focus on progressing its novel and differentiated back of the eye drug candidate targeting potential market opportunities of over USD 5 billion. Leuven, BELGIUM, Boston,

  • GlobeNewswire

    Oxurion Provides Further Details Concerning the Second Amendment to Negma Funding Program

    Oxurion Provides Further Details Concerning the Second Amendment to Negma Funding Program Leuven, BELGIUM, Boston, MA, US – January 26, 2023 8:00 am CET – Oxurion NV (Euronext Brussels: OXUR) a biopharmaceutical company developing next generation standard of care ophthalmic therapies, with clinical stage assets in vascular retinal disorders, has entered into an amendment of its mandatory convertible bonds issuance and subscription agreement with the Negma Group on January 25, 2023 (“funding prog

  • GlobeNewswire

    Oxurion Announces Second Amendment to Negma Funding Program

    Oxurion Announces Second Amendment to Negma Funding Program Leuven, BELGIUM, Boston, MA, US – January 25, 2023 8:30 am – Oxurion NV (Euronext Brussels: OXUR) a biopharmaceutical company developing next generation standard of care ophthalmic therapies, with clinical stage assets in vascular retinal disorders, announced today that it has further amended its mandatory convertible bonds issuance and subscription agreement with the Negma Group (“funding program”). Since the start of the funding progr